Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.
Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...
In a report released today, Steve Scala from TD Cowen maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
Like many pharma stocks, Eli Lilly (NYSE: LLY ... Lilly's revenue climb in the double digits in recent quarters and the stock price to take off. The shares have advanced more than 200% over ...
First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...
Citi analyst Geoff Meacham reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,190.00. The ...
Shares of Sangamo Therapeutics climbed after the genomic medicine company entered a licensing agreement with Eli Lilly for STAC-BBB. The stock rose 31% to 81 cents on volume of 3.1 million shares in ...
Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments.